

Clozapine – Updated labeling and elimination of REMS

- On June 13, 2025, the FDA approved updating labeling for clozapine products (<u>Clozaril®</u>, <u>Versacloz®</u>) and <u>officially eliminated the Clozapine Risk Evaluation and Mitigation Strategies</u> (<u>REMS</u>) program for these products.
- This approval follows the February 24, 2025 <u>announcement</u> that the FDA did not expect
 prescribers, pharmacies, and patients to participate in the <u>REMS program</u> for clozapine or to
 report results of absolute neutrophil count (ANC) blood tests before pharmacies dispense
 clozapine.
- Although the risk of severe neutropenia with clozapine still exists, FDA has determined that the Clozapine REMS is no longer necessary to ensure the benefits of the medicine outweigh that risk.
 - Eliminating the REMS is expected to decrease the burden on the health care delivery system and improve access to clozapine.
- FDA still recommends that prescribers monitor patients' ANC according to the monitoring frequencies described in the prescribing information. Information about severe neutropenia remains in the prescribing information for all clozapine medicines, including in the existing Boxed Warnings, and ANC monitoring frequencies are unchanged.
- Clozapine products are approved for treatment-resistant schizophrenia and reduction in the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.